These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10562485)

  • 1. Assessment of risk of thromboembolism in atrial fibrillation: which patients should be anticoagulated?
    Lip GY
    Eur Heart J; 1999 Dec; 20(23):1757-8. PubMed ID: 10562485
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of transesophageal echocardiography in deciding the treatment patients with atrial fibrillation].
    Bykova ES; Golitsyn SP; At'kov OIu
    Ter Arkh; 2001; 73(8):77-80. PubMed ID: 11599276
    [No Abstract]   [Full Text] [Related]  

  • 3. [Value of transesophageal echocardiography in the therapeutic management of non-valvular atrial fibrillation].
    Baubion N
    Arch Mal Coeur Vaiss; 1996 Oct; 89(10):1291-5. PubMed ID: 8952827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients undergoing cardioversion of atrial flutter should be routinely anticoagulated.
    Densèm CG
    Am J Cardiol; 1999 Jan; 83(1):140-1. PubMed ID: 10073808
    [No Abstract]   [Full Text] [Related]  

  • 5. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis.
    Lip GY
    Thromb Haemost; 2008 Jul; 100(1):11-3. PubMed ID: 18612530
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of atrial fibrillation burden in assessing thromboembolic risk.
    Zimetbaum P; Waks JW; Ellis ER; Glotzer TV; Passman RS
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1223-9. PubMed ID: 25516580
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
    Tebbe U
    Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
    [No Abstract]   [Full Text] [Related]  

  • 8. When the body and appendage of the left atrium disagree: "Focal" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism.
    Seto TB; Buchholz WA; Douglas PS; Manning WJ
    J Am Soc Echocardiogr; 1999 Dec; 12(12):1097-100. PubMed ID: 10588786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 10. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

  • 11. Managing anticoagulated atrial fibrillation patients undergoing endoscopy.
    Gorard DA
    Gut; 2009 Mar; 58(3):468; author reply 469. PubMed ID: 19211861
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation.
    Abumuaileq RR; Abu-Assi E; López-López A; Raposeiras-Roubin S; Rodríguez-Mañero M; Martínez-Sande L; García-Seara J; Fernandez-López XA; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2015 Nov; 15():156. PubMed ID: 26584938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboembolism after negative TEE.
    Manning WJ; Silverman DI; Douglas PS
    Circulation; 1994 Dec; 90(6):3121-2. PubMed ID: 7994865
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antithrombotic therapy in patients with chronic atrial fibrillation].
    Gardella A; Casanovas M; Marina V; Pascual C
    Aten Primaria; 1994 Nov; 14(9):1094. PubMed ID: 7529057
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy.
    Mitusch R; Siemens HJ; Garbe M; Wagner T; Sheikhzadeh A; Diederich KW
    Thromb Haemost; 1996 Feb; 75(2):219-23. PubMed ID: 8815563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.
    Lang NN; Connelly DT
    J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Executive summary: Prevention of thromboembolic events: the role of point of care management.
    J Heart Valve Dis; 2007 Mar; 16(2):184-6. PubMed ID: 17607861
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antithrombotic treatment in auricular fibrillation].
    Juncadella E; Alba J; Roser C; Fandos JM
    Aten Primaria; 1995 Jun; 16(2):116-7. PubMed ID: 7626732
    [No Abstract]   [Full Text] [Related]  

  • 19. Anticoagulation in people with atrial fibrillation.
    Fang MC
    BMJ; 2011 Jan; 342():d530. PubMed ID: 21282259
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.